LOGIN 

 

JOIN

 

RENEW

 

CME/MOC

Journal Club/Webinar

HomeMembersAssemblies and SectionsAssembliesAllergy, Immunology and InflammationJournal Club/Webinar ▶ Reduction of Daily Maintenance Inhaled Corticosteroids In Patients with Severe Eosinophilic Asthma Treated With Benralizumab (SHAMAL): A randomized, multicenter, open-label, phase 4 study
Reduction of Daily Maintenance Inhaled Corticosteroids In Patients with Severe Eosinophilic Asthma Treated With Benralizumab (SHAMAL): A randomized, multicenter, open-label, phase 4 study

Webinar date: Tuesday, April 16th 2024

Presenters:

David Jackson, MBBS, MRCP, MSc, PhD

Helen Reddel, MBBS, PhD, FRACP 

WIlliam Feldman, MD, DPhil, MPH

Moderators:

Amit Bery, MD

Vickram Tejwani, MD